NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Shuttle Pharmaceuticals Holdings Inc is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.
Shuttle Pharmaceuticals Holdings acquired Molecule.ai, a pharmaceutical software company offering an artificial intelligence platform to assist researchers in drug discovery and development. The system combines AI techniques with scientific workflows to help explore chemical compounds, assess molecular candidates and support decision-making during early research phases. The company is discontinuing its clinical trials of Ropidoxuridine.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Shuttle Pharmaceuticals Holdings Inc stock.
Not valued: We cannot value this company yet.
All 82 Drug Manufacturers - Specialty & Generic stocks
33 more in this industry show a wider margin of safety.
We do not publish a verdict on SHPH yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.